drugset / Trial / NCT06574347
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
RandomizedParallel-groupOpen-labelTreatment
Summary
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Timeline
- Start
- 2024-08-07
- Primary completion
- 2026-10-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Osimertinib | Small molecule | 80 mg | Oral |
| Subject | PLB1004 | Small molecule | 80 mg | Oral |
| Subject | Vebreltinib | Small molecule | 150 mg | Oral |